Index - 2020

2021 / 2020 / 2019 / 2018



  • Other
  • Main articleH
  • Attention!LO
  • New
A
ACE inhibitors NSAID 2020 angiotensin II receptor antagonists 2020 coronavirus 2020 corticosteroids 2020 covid-19 2020 pioglitazone 2020 sars-cov-2 2020 Achilles tendon rupture ACP 202052-55 PRP 202052-55 autologous conditioned plasma 202052-55 autologous platelet-rich plasma 202052-55 platelet-rich plasma 202052-55 rotator cuff rupture 202052-55 soft tissue injuries 202052-55 tendinopathy 202052-55 ACP Achilles tendon rupture 202052-55 PRP 202052-55 autologous conditioned plasma 202052-55 autologous platelet-rich plasma 202052-55 platelet-rich plasma 202052-55 rotator cuff rupture 202052-55 soft tissue injuries 202052-55 tendinopathy 202052-55 acute chest syndrome hydroxycarbamide 202057-64 pain episodes 202057-64 sickle cell disease 202057-64 anakinra C1-esterase inhibitor 202067-78 azithromycin 202067-78 chloroquine 202067-78 covid-19 202067-78 hydroxychloroquine 202067-78 icatibant 202067-78 lanadelumab 202067-78 lopinavir 202067-78 remdesivir 202067-78 ritonavir 202067-78 sars-cov-2 202067-78 tocilizumab 202067-78 valsartan 202067-78 zinc 202067-78 angiotensin II receptor antagonists ACE inhibitors 2020 NSAID 2020 coronavirus 2020 corticosteroids 2020 covid-19 2020 pioglitazone 2020 sars-cov-2 2020 antibiotic-resistant bacteria H2 antagonists 202085-88 PPIs 202085-88 gastric acid-suppressive agent 202085-88 intestinal colonisation 202085-88 reboundeffect 202085-88 antithrombotic CYP2C19 20209-14 Cytochrome P450 20209-14 PCI 20209-14 clopidogrel 20209-14 genotyping 20209-14 autologous conditioned plasma ACP 202052-55 Achilles tendon rupture 202052-55 PRP 202052-55 autologous platelet-rich plasma 202052-55 platelet-rich plasma 202052-55 rotator cuff rupture 202052-55 soft tissue injuries 202052-55 tendinopathy 202052-55 autologous platelet-rich plasma ACP 202052-55 Achilles tendon rupture 202052-55 PRP 202052-55 autologous conditioned plasma 202052-55 platelet-rich plasma 202052-55 rotator cuff rupture 202052-55 soft tissue injuries 202052-55 tendinopathy 202052-55 azithromycin C1-esterase inhibitor 202067-78 anakinra 202067-78 chloroquine 202067-78 covid-19 202067-78 hydroxychloroquine 202067-78 icatibant 202067-78 lanadelumab 202067-78 lopinavir 202067-78 remdesivir 202067-78 ritonavir 202067-78 sars-cov-2 202067-78 tocilizumab 202067-78 valsartan 202067-78 zinc 202067-78
B
Ballerine Pearl Index 2020123-127 contraception 2020123-127 copper IUD 2020123-127 copper-containing IUD 2020123-127 medical device 2020123-127 notified body 2020123-127 pregnancy 2020123-127 bias RCT 20201-8 consistency check 202089-95 drugs ranking 202089-95 effect modifier 202089-95 network meta-analysis 202089-95 observational 20201-8 randomised 20201-8 research 20201-8 statistical test 202089-95 breast cancer hormone therapy 202022-27 menopausal symptoms 202022-27 breast implant lymphoma 2020
C
C1-esterase inhibitor anakinra 202067-78 azithromycin 202067-78 chloroquine 202067-78 covid-19 202067-78 hydroxychloroquine 202067-78 icatibant 202067-78 lanadelumab 202067-78 lopinavir 202067-78 remdesivir 202067-78 ritonavir 202067-78 sars-cov-2 202067-78 tocilizumab 202067-78 valsartan 202067-78 zinc 202067-78 cardiovascular mortality Entresto 2020 enalapril 2020 heart failure 2020 sacubitril 2020 valsartan 2020 chloroquine C1-esterase inhibitor 202067-78 anakinra 202067-78 azithromycin 202067-78 covid-19 202067-78 hydroxychloroquine 202067-78 icatibant 202067-78 lanadelumab 202067-78 lopinavir 202067-78 remdesivir 202067-78 ritonavir 202067-78 sars-cov-2 202067-78 tocilizumab 202067-78 valsartan 202067-78 zinc 202067-78 clopidogrel CYP2C19 20209-14 Cytochrome P450 20209-14 PCI 20209-14 antithrombotic 20209-14 genotyping 20209-14 consistency check bias 202089-95 drugs ranking 202089-95 effect modifier 202089-95 network meta-analysis 202089-95 statistical test 202089-95 contaminations drug contamination 2020121-122 impurities 2020121-122 preparations 2020121-122 production process 2020121-122 quality control 2020121-122 valsartan 2020121-122 contraception Ballerine 2020123-127 Pearl Index 2020123-127 copper IUD 2020123-127 copper-containing IUD 2020123-127 medical device 2020123-127 notified body 2020123-127 pregnancy 2020123-127 copper IUD Ballerine 2020123-127 Pearl Index 2020123-127 contraception 2020123-127 copper-containing IUD 2020123-127 medical device 2020123-127 notified body 2020123-127 pregnancy 2020123-127 copper-containing IUD Ballerine 2020123-127 Pearl Index 2020123-127 contraception 2020123-127 copper IUD 2020123-127 medical device 2020123-127 notified body 2020123-127 pregnancy 2020123-127 coronavirus ACE inhibitors 2020 NSAID 2020 angiotensin II receptor antagonists 2020 corticosteroids 2020 covid-19 2020 pioglitazone 2020 sars-cov-2 2020 corticosteroids ACE inhibitors 2020 NSAID 2020 angiotensin II receptor antagonists 2020 coronavirus 2020 covid-19 2020 pioglitazone 2020 sars-cov-2 2020 covid-19 ACE inhibitors 2020 C1-esterase inhibitor 202067-78 NSAID 2020 anakinra 202067-78 angiotensin II receptor antagonists 2020 azithromycin 202067-78 chloroquine 202067-78 coronavirus 2020 corticosteroids 2020 hydroxychloroquine 202067-78 icatibant 202067-78 lanadelumab 202067-78 lopinavir 202067-78 pioglitazone 2020 remdesivir 202067-78 ritonavir 202067-78 sars-cov-2 2020 sars-cov-2 202067-78 tocilizumab 202067-78 valsartan 202067-78 zinc 202067-78 CYP enzymes drug interaction 202015-20 CYP2C19 Cytochrome P450 20209-14 PCI 20209-14 antithrombotic 20209-14 clopidogrel 20209-14 genotyping 20209-14 Cytochrome P450 CYP2C19 20209-14 PCI 20209-14 antithrombotic 20209-14 clopidogrel 20209-14 genotyping 20209-14
D
drug contamination contaminations 2020121-122 impurities 2020121-122 preparations 2020121-122 production process 2020121-122 quality control 2020121-122 valsartan 2020121-122 drug interaction CYP enzymes 202015-20 drugs ranking bias 202089-95 consistency check 202089-95 effect modifier 202089-95 network meta-analysis 202089-95 statistical test 202089-95
E
effect modifier bias 202089-95 consistency check 202089-95 drugs ranking 202089-95 network meta-analysis 202089-95 statistical test 202089-95 enalapril Entresto 2020 cardiovascular mortality 2020 heart failure 2020 sacubitril 2020 valsartan 2020 Entresto cardiovascular mortality 2020 enalapril 2020 heart failure 2020 sacubitril 2020 valsartan 2020
G
gastric acid-suppressive agent H2 antagonists 202085-88 PPIs 202085-88 antibiotic-resistant bacteria 202085-88 intestinal colonisation 202085-88 reboundeffect 202085-88 genotyping CYP2C19 20209-14 Cytochrome P450 20209-14 PCI 20209-14 antithrombotic 20209-14 clopidogrel 20209-14
H
H2 antagonists PPIs 202085-88 antibiotic-resistant bacteria 202085-88 gastric acid-suppressive agent 202085-88 intestinal colonisation 202085-88 reboundeffect 202085-88 heart failure Entresto 2020 cardiovascular mortality 2020 enalapril 2020 sacubitril 2020 valsartan 2020 herpes zoster Shingrix 202097-101 postherpetic neuralgia 202097-101 vaccination programme 202097-101 vaccine 202097-101 hormone therapy breast cancer 202022-27 menopausal symptoms 202022-27 hydroxycarbamide acute chest syndrome 202057-64 pain episodes 202057-64 sickle cell disease 202057-64 hydroxychloroquine C1-esterase inhibitor 202067-78 anakinra 202067-78 azithromycin 202067-78 chloroquine 202067-78 covid-19 202067-78 icatibant 202067-78 lanadelumab 202067-78 lopinavir 202067-78 remdesivir 202067-78 ritonavir 202067-78 sars-cov-2 202067-78 tocilizumab 202067-78 valsartan 202067-78 zinc 202067-78
I
icatibant C1-esterase inhibitor 202067-78 anakinra 202067-78 azithromycin 202067-78 chloroquine 202067-78 covid-19 202067-78 hydroxychloroquine 202067-78 lanadelumab 202067-78 lopinavir 202067-78 remdesivir 202067-78 ritonavir 202067-78 sars-cov-2 202067-78 tocilizumab 202067-78 valsartan 202067-78 zinc 202067-78 impurities contaminations 2020121-122 drug contamination 2020121-122 preparations 2020121-122 production process 2020121-122 quality control 2020121-122 valsartan 2020121-122 interventions overviews 2020117-120 umbrella review 2020117-120 intestinal colonisation H2 antagonists 202085-88 PPIs 202085-88 antibiotic-resistant bacteria 202085-88 gastric acid-suppressive agent 202085-88 reboundeffect 202085-88
L
lanadelumab C1-esterase inhibitor 202067-78 anakinra 202067-78 azithromycin 202067-78 chloroquine 202067-78 covid-19 202067-78 hydroxychloroquine 202067-78 icatibant 202067-78 lopinavir 202067-78 remdesivir 202067-78 ritonavir 202067-78 sars-cov-2 202067-78 tocilizumab 202067-78 valsartan 202067-78 zinc 202067-78 lopinavir C1-esterase inhibitor 202067-78 anakinra 202067-78 azithromycin 202067-78 chloroquine 202067-78 covid-19 202067-78 hydroxychloroquine 202067-78 icatibant 202067-78 lanadelumab 202067-78 remdesivir 202067-78 ritonavir 202067-78 sars-cov-2 202067-78 tocilizumab 202067-78 valsartan 202067-78 zinc 202067-78 lymphoma breast implant 2020
M
medical device Ballerine 2020123-127 Pearl Index 2020123-127 contraception 2020123-127 copper IUD 2020123-127 copper-containing IUD 2020123-127 notified body 2020123-127 pregnancy 2020123-127 melatonine sleep disorders 202041-44 menopausal symptoms breast cancer 202022-27 hormone therapy 202022-27 mortality rate vitamin B12 202065-66 vitamin B12 deficiency 202065-66 vitamin B12 supplementation 202065-66
N
network meta-analysis bias 202089-95 consistency check 202089-95 drugs ranking 202089-95 effect modifier 202089-95 statistical test 202089-95 notified body Ballerine 2020123-127 Pearl Index 2020123-127 contraception 2020123-127 copper IUD 2020123-127 copper-containing IUD 2020123-127 medical device 2020123-127 pregnancy 2020123-127 NSAID ACE inhibitors 2020 angiotensin II receptor antagonists 2020 coronavirus 2020 corticosteroids 2020 covid-19 2020 pioglitazone 2020 sars-cov-2 2020
O
observational RCT 20201-8 bias 20201-8 randomised 20201-8 research 20201-8 omega-3 fatty acids premature birth 202079-84 type 2 diabetes 202079-84 overviews interventions 2020117-120 umbrella review 2020117-120
P
pain episodes acute chest syndrome 202057-64 hydroxycarbamide 202057-64 sickle cell disease 202057-64 PCI CYP2C19 20209-14 Cytochrome P450 20209-14 antithrombotic 20209-14 clopidogrel 20209-14 genotyping 20209-14 Pearl Index Ballerine 2020123-127 contraception 2020123-127 copper IUD 2020123-127 copper-containing IUD 2020123-127 medical device 2020123-127 notified body 2020123-127 pregnancy 2020123-127 pioglitazone ACE inhibitors 2020 NSAID 2020 angiotensin II receptor antagonists 2020 coronavirus 2020 corticosteroids 2020 covid-19 2020 sars-cov-2 2020 platelet-rich plasma ACP 202052-55 Achilles tendon rupture 202052-55 PRP 202052-55 autologous conditioned plasma 202052-55 autologous platelet-rich plasma 202052-55 rotator cuff rupture 202052-55 soft tissue injuries 202052-55 tendinopathy 202052-55 postherpetic neuralgia Shingrix 202097-101 herpes zoster 202097-101 vaccination programme 202097-101 vaccine 202097-101 PPIs H2 antagonists 202085-88 antibiotic-resistant bacteria 202085-88 gastric acid-suppressive agent 202085-88 intestinal colonisation 202085-88 reboundeffect 202085-88 pregnancy Ballerine 2020123-127 Pearl Index 2020123-127 contraception 2020123-127 copper IUD 2020123-127 copper-containing IUD 2020123-127 medical device 2020123-127 notified body 2020123-127 premature birth omega-3 fatty acids 202079-84 type 2 diabetes 202079-84 preparations contaminations 2020121-122 drug contamination 2020121-122 impurities 2020121-122 production process 2020121-122 quality control 2020121-122 valsartan 2020121-122 production process contaminations 2020121-122 drug contamination 2020121-122 impurities 2020121-122 preparations 2020121-122 quality control 2020121-122 valsartan 2020121-122 PRP ACP 202052-55 Achilles tendon rupture 202052-55 autologous conditioned plasma 202052-55 autologous platelet-rich plasma 202052-55 platelet-rich plasma 202052-55 rotator cuff rupture 202052-55 soft tissue injuries 202052-55 tendinopathy 202052-55
Q
quality control contaminations 2020121-122 drug contamination 2020121-122 impurities 2020121-122 preparations 2020121-122 production process 2020121-122 valsartan 2020121-122
R
randomised RCT 20201-8 bias 20201-8 observational 20201-8 research 20201-8 RCT bias 20201-8 observational 20201-8 randomised 20201-8 research 20201-8 reboundeffect H2 antagonists 202085-88 PPIs 202085-88 antibiotic-resistant bacteria 202085-88 gastric acid-suppressive agent 202085-88 intestinal colonisation 202085-88 remdesivir C1-esterase inhibitor 202067-78 anakinra 202067-78 azithromycin 202067-78 chloroquine 202067-78 covid-19 202067-78 hydroxychloroquine 202067-78 icatibant 202067-78 lanadelumab 202067-78 lopinavir 202067-78 ritonavir 202067-78 sars-cov-2 202067-78 tocilizumab 202067-78 valsartan 202067-78 zinc 202067-78 research RCT 20201-8 bias 20201-8 observational 20201-8 randomised 20201-8 ritonavir C1-esterase inhibitor 202067-78 anakinra 202067-78 azithromycin 202067-78 chloroquine 202067-78 covid-19 202067-78 hydroxychloroquine 202067-78 icatibant 202067-78 lanadelumab 202067-78 lopinavir 202067-78 remdesivir 202067-78 sars-cov-2 202067-78 tocilizumab 202067-78 valsartan 202067-78 zinc 202067-78 rotator cuff rupture ACP 202052-55 Achilles tendon rupture 202052-55 PRP 202052-55 autologous conditioned plasma 202052-55 autologous platelet-rich plasma 202052-55 platelet-rich plasma 202052-55 soft tissue injuries 202052-55 tendinopathy 202052-55
S
sacubitril Entresto 2020 cardiovascular mortality 2020 enalapril 2020 heart failure 2020 valsartan 2020 sars-cov-2 ACE inhibitors 2020 C1-esterase inhibitor 202067-78 NSAID 2020 anakinra 202067-78 angiotensin II receptor antagonists 2020 azithromycin 202067-78 chloroquine 202067-78 coronavirus 2020 corticosteroids 2020 covid-19 2020 covid-19 202067-78 hydroxychloroquine 202067-78 icatibant 202067-78 lanadelumab 202067-78 lopinavir 202067-78 pioglitazone 2020 remdesivir 202067-78 ritonavir 202067-78 tocilizumab 202067-78 valsartan 202067-78 zinc 202067-78 Shingrix herpes zoster 202097-101 postherpetic neuralgia 202097-101 vaccination programme 202097-101 vaccine 202097-101 sickle cell disease acute chest syndrome 202057-64 hydroxycarbamide 202057-64 pain episodes 202057-64 sleep disorders melatonine 202041-44 soft tissue injuries ACP 202052-55 Achilles tendon rupture 202052-55 PRP 202052-55 autologous conditioned plasma 202052-55 autologous platelet-rich plasma 202052-55 platelet-rich plasma 202052-55 rotator cuff rupture 202052-55 tendinopathy 202052-55 statistical test bias 202089-95 consistency check 202089-95 drugs ranking 202089-95 effect modifier 202089-95 network meta-analysis 202089-95
T
tendinopathy ACP 202052-55 Achilles tendon rupture 202052-55 PRP 202052-55 autologous conditioned plasma 202052-55 autologous platelet-rich plasma 202052-55 platelet-rich plasma 202052-55 rotator cuff rupture 202052-55 soft tissue injuries 202052-55 tocilizumab C1-esterase inhibitor 202067-78 anakinra 202067-78 azithromycin 202067-78 chloroquine 202067-78 covid-19 202067-78 hydroxychloroquine 202067-78 icatibant 202067-78 lanadelumab 202067-78 lopinavir 202067-78 remdesivir 202067-78 ritonavir 202067-78 sars-cov-2 202067-78 valsartan 202067-78 zinc 202067-78 type 2 diabetes omega-3 fatty acids 202079-84 premature birth 202079-84
U
umbrella review interventions 2020117-120 overviews 2020117-120
V
vaccination programme Shingrix 202097-101 herpes zoster 202097-101 postherpetic neuralgia 202097-101 vaccine 202097-101 vaccine Shingrix 202097-101 herpes zoster 202097-101 postherpetic neuralgia 202097-101 vaccination programme 202097-101 valsartan C1-esterase inhibitor 202067-78 Entresto 2020 anakinra 202067-78 azithromycin 202067-78 cardiovascular mortality 2020 chloroquine 202067-78 contaminations 2020121-122 covid-19 202067-78 drug contamination 2020121-122 enalapril 2020 heart failure 2020 hydroxychloroquine 202067-78 icatibant 202067-78 impurities 2020121-122 lanadelumab 202067-78 lopinavir 202067-78 preparations 2020121-122 production process 2020121-122 quality control 2020121-122 remdesivir 202067-78 ritonavir 202067-78 sacubitril 2020 sars-cov-2 202067-78 tocilizumab 202067-78 zinc 202067-78 vitamin B12 mortality rate 202065-66 vitamin B12 deficiency 202065-66 vitamin B12 supplementation 202065-66 vitamin B12 deficiency mortality rate 202065-66 vitamin B12 202065-66 vitamin B12 supplementation 202065-66 vitamin B12 supplementation mortality rate 202065-66 vitamin B12 202065-66 vitamin B12 deficiency 202065-66
Z
zinc C1-esterase inhibitor 202067-78 anakinra 202067-78 azithromycin 202067-78 chloroquine 202067-78 covid-19 202067-78 hydroxychloroquine 202067-78 icatibant 202067-78 lanadelumab 202067-78 lopinavir 202067-78 remdesivir 202067-78 ritonavir 202067-78 sars-cov-2 202067-78 tocilizumab 202067-78 valsartan 202067-78